Owkin is an AI biotechnology company specializing in utilizing artificial intelligence to facilitate patient-specific treatment discovery. By bridging the gap between complex biology and innovative therapies, Owkin accelerates clinical trials, identifies novel treatments, and develops diagnostic tools. With an emphasis on safeguarding patient privacy and proprietary data, Owkin implements federated learning, an advanced collaborative AI framework, to extract valuable insights from diverse datasets. Collaborating with esteemed academic institutions, Owkin curates and enriches multimodal data for AI-driven biomedical research. Additionally, Owkin is developing Abstra, a metadata catalog technology platform, designed to expedite the discovery of research collaborators and datasets, thereby enhancing AI biomedical research.
Yes. Owkin is a private venture-backed company. Investors usually purchase preferred stock and employees typically receive common stock options or restricted stock units (RSUs) as part of their compensation.
Since it is not publicly listed, there is no Owkin stock symbol or Owkin ticker symbol assigned for Owkin.
Private companies typically reserve a stock symbol up to two years prior to an IPO, and disclose this when they file a Form S-1 with the Security Exchange Commission when they start the IPO process.
If you own shares of a private company, it may be possible to find liquidity for your holdings before the company goes public. Finding the right private market broker can make all the difference as the best brokers can leverage deep industry relationships and negotiate on your behalf.
If you are interested in selling private stock you can reach out to Premier brokers for more information.
Private market transactions can be complex and may involve company approvals, legal purchase agreements and wires to third parties. Trades can take 30 - 60 days to complete which is why many investors work with experienced private market brokers to help guide the process.
Direct share transfers typically require issuer approvals. Issuers may exercise the right of first refusal (ROFR) in order to direct the seller to a buyer of their choosing.
Some issuers do not allow transactions. In these cases, buyers will need to purchase indirect interests in the business via special purpose vehicles (SPVs) or forward purchase contracts (forwards).
Owkin stock does not trade publicly on Nasdaq or NYSE because it is still a private company. Owkin stock might be available for purchase in the secondary markets, but Owkin stock is not available for purchase by the general public, and can not be purchased through traditional brokerage accounts.
Only accredited investors and qualified purchasers can buy private stock. These investors buy pre-IPO stock in the secondary market from existing employees and investors.
To learn more about the market for Owkin stock, talk to the best brokers on the planet.
Accredited investors can purchase shares in private companies like Owkin. Investors can rely on Notice Premier Brokers to find supply and guide them through the trading process.
Because Owkin is privately held, its stock is not available for purchase through public stock exchanges like the NYSE or Nasdaq. Retail investors can not access this stock via traditional brokerage accounts, and are not allowed to invest directly in Owkin pre-IPO.
Notice Price is algorithmically generated based on a number of inputs like private market activity, official company filings, internal marks, and comparables.
Developing accurate pricing for the private market, and making that pricing available to everyone has always been our mission.